NICE guidance on necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer

Umeweni, Nwamaka; Knight, Helen; McVeigh, Gary E.

doi:10.1016/s1470-2045(16)30488-0

Cited by 3 publications

(1 citation statement)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The intermediate survival period was 12.2 months (95% CI, 9.7-15.0) for nivolumab and 9.4 months (95% CI, 8.1-10.7) for docetaxel, and the response rate was higher for nivolumab than for docetaxel (19% vs 12%, p = 0.02). Nivolumab has been changed the guideline development and revision of the NSCLC and other solid cancer treatment (2)(3)(4)(5). New classes of drugs (e.g.…”

Section: Introductionmentioning

confidence: 99%

Association of Diabetes Status With Survival After Immune Checkpoint Inhibitor Treatment for Advanced Lung Cancer: a Retrospective Study in Japan

Hisanaga

Uchino

Kakisu

et al. 2020

Preprint

View full text Add to dashboard Cite

Introduction: Although immune checkpoint inhibitors (ICIs) are promising in the treatment of advanced cancer, they may lead to immune-related adverse events (irAEs), which can affect endocrine organ systems. However, development of the irAEs was associated with improved cancer-specific survival, the risk for years have not been elucidated. We investigated the association of pre-ICI comorbidities—including diabetes—with years and overall survival (OS) and progression-free survival (PFS) in advanced lung cancer. Research design and methods: Patients with lung cancer who were treated with ICIs at the period from September 1, 2015 through July 31, 2018 were retrospectively enrolled. All data were collected from the university patient NEPTUNE database. Hazard ratios were estimated by using Cox regression weighted for propensity scores. Odds ratios were calculated by logistic regression and adjusted for unbalanced variables. The Kaplan–Meier method was used to compare OS, and the generalized Wilcoxon test was used to compare median survival. The results: Among the 88 patients identified, 22 (25.0%) had diabetes (DM) before ICI treatment and 57 (75.0%) did not (non-DM). Iris developed in 12.2% of patients with DM and in 9.1% of patients in non-DM (p=0.87). Diabetes status was not associated with auras risk in relation to baseline characteristics (age, sex, TNM staging, thyroid and renal function) or after propensity score matching analysis (age, TNM staging). During a mean follow-up of 30 months, OS and cancer-specific PFS were significantly higher in patients who developed iris (Kaplan–Meier estimates, p=0·04 and 0·03, respectively). In propensity score–matched analysis, diabetes was significantly associated with lower OS (multivariate hazard ratio, 0·36; 95% CI, 0·13–0·98). Irrespective of eras, PFS was lower among patients with DM than among non-DM (Kaplan–Meier estimate, p=0·04). Conclusions: Pre-existing diabetes was associated with higher mortality in advanced lung cancer, regardless of irAEs development after treatment with ICIs.

show abstract

Section: Introductionmentioning

confidence: 99%

Association of Diabetes Status With Survival After Immune Checkpoint Inhibitor Treatment for Advanced Lung Cancer: a Retrospective Study in Japan

Hisanaga

Uchino

Kakisu

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature

2017

View full text Add to dashboard Cite

Lung cancer remains the leading cause of cancer-related death and economic burden worldwide. Despite the heavy toll of lung cancer, multiple new advances have improved patient outcomes, largely through precision medicine and targeted therapy. The associated rising economic burden however may impact the uptake of novel therapeutic agents in lung cancer, thereby limiting patient access. This article identifies and reviews economic evaluations of targeted agents in lung cancer in the era of precision medicine. Articles evaluating biomarker-directed test-and-treat strategies are also reviewed to evaluate the cost impact of novel therapeutic agents at a population level. The Quality of Health Economic Studies instrument is applied to assess the quality of included studies. Forty-six studies are reviewed and encompass studies of epidermal growth factor receptor inhibitors and monoclonal antibodies, anaplastic lymphoma kinase inhibitors, vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors and immunotherapy (programmed death-1 inhibitors). Key factors influencing results of economic analyses include comparators chosen, perspective used, magnitude of clinical benefit, utility weighting of outcomes and drug acquisition costs. Biomarker-driven decision making should be integrated into cost evaluations given the important role of molecular testing for individualising treatment for non-small-cell lung cancer. We conclude that despite major clinical advances in lung cancer therapeutics, cost remains an important consideration in the adoption of novel therapies.

show abstract

Pre-Existing Diabetes Limits Survival Rate After Immune Checkpoint Inhibitor Treatment for Advanced Lung Cancer: A Retrospective Study in Japan

Hisanaga¹,

Uchino²,

Kakisu³

et al. 2021

DMSO

View full text Add to dashboard Cite

Background Although immune checkpoint inhibitors (ICIs) are promising in the treatment of advanced cancer, their use is associated with immune-related adverse events (irAEs) that affect endocrine organ systems. Although development of irAEs was associated with improved cancer-specific survival, the risk of irAEs is unclear. We investigated the association of pre-ICI comorbidities—including diabetes—with irAEs, overall survival (OS), and progression-free survival (PFS) in advanced lung cancer. Methods Patients with lung cancer who were treated with ICIs during the period from September 1, 2015 through July 31, 2018 were retrospectively enrolled. All data were collected from the NEPTUNE database of university patients. Hazard ratios were estimated by using Cox regression weighted for propensity scores. Odds ratios were calculated by logistic regression and adjusted for unbalanced variables. The Kaplan–Meier method was used to compare OS, and the generalized Wilcoxon test was used to compare median survival. Results Among the 88 patients identified, 22 (25.0%) had diabetes (DM) before ICI treatment and 57 (75.0%) did not (non-DM); irAEs developed in 12.2% of patients with DM and in 9.1% of patients in non-DM (p=0.87). Diabetes status was not associated with irAE risk in relation to baseline characteristics (age, sex, TNM staging, thyroid and renal function) or in propensity score–matched analysis (age, TNM staging). During a mean follow-up of 30 months, OS and cancer-specific PFS were significantly higher in patients who developed irAEs (Kaplan–Meier estimates, p=0·04 and 0·03, respectively). In propensity score–matched analysis, diabetes was significantly associated with lower OS (multivariate hazard ratio, 0·36; 95% CI, 0·13–0·98) unrelated to irAEs. Irrespective of irAEs, PFS was also lower among patients with DM than among non-DM patients (Kaplan–Meier estimate, p=0·04). Conclusion Pre-existing diabetes was associated with higher mortality in advanced lung cancer, regardless of irAE development during treatment with ICI.

show abstract

NICE guidance on necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer

Cited by 3 publications

References 2 publications

Association of Diabetes Status With Survival After Immune Checkpoint Inhibitor Treatment for Advanced Lung Cancer: a Retrospective Study in Japan

Association of Diabetes Status With Survival After Immune Checkpoint Inhibitor Treatment for Advanced Lung Cancer: a Retrospective Study in Japan

Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature

Pre-Existing Diabetes Limits Survival Rate After Immune Checkpoint Inhibitor Treatment for Advanced Lung Cancer: A Retrospective Study in Japan

Contact Info

Product

Resources

About